← Back
$LRMR All transactions

Larimar Therapeutics, Inc.

▲ BUY
10 / 10

Conviction

$ Value

$10.8M

Shares

3,387,529

Price

$3

Filed

Aug 4

Why this score? (10/10)
  • Open market buy (+3)
  • Trade value >= $5.0M (+3)
  • % of holdings >= 20% (+2)
  • Director (+1)
  • 10%+ owner (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Flynn James E

Title

CIK

0001352546

Roles

Director 10% Owner Other

Transaction Details

Transaction Date

2025-07-31

Code

P

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

9,538,918

Footnotes

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. | In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Filing Info

Accession No.

0001193805-25-001155

Form Type

4

Issuer CIK

0001374690

Flynn James E's History

Date Ticker Type Value
2025-11-24 NUVL $35.4M
2025-11-24 NUVL $35.4M
2025-07-31 LRMR $10.8M
2025-07-31 LRMR $10.8M
2025-07-31 LRMR $8.3M
2025-06-27 SPRY $6.8M
2025-06-27 SPRY $6.8M
2025-06-18 NUVL A $0
2025-06-18 NUVL A $0
2025-06-18 NUVL A $0

Other Insiders at LRMR (90d)

Insider Bought Sold Last
Celano Michael
Chief Financial Officer
2026-01-26
BEN-MAIMON CAROLE
President and CEO
2026-01-26
Clayton Russell
Chief Medical Officer
2026-01-26
Shankar Gopi
Chief Development Officer
2026-01-26